Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.

G Blackledge1, W P Steward, J Verweij

  • 1University of Birmingham, UK.

Seminars in Oncology
|February 1, 1992
PubMed
Summary

Chemotherapy regimens for advanced soft tissue and bone sarcomas are evolving. Studies show doxorubicin and ifosfamide combinations are promising, with new trials investigating optimized doses for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring early traumatic experiences as differential diagnostic factors between bipolar disorder and borderline personality disorder.

Journal of affective disorders·2025
Same author

[Trisomy 18: how lethal is 'lethal'?]

Nederlands tijdschrift voor geneeskunde·2017
Same author

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Breast cancer research and treatment·2017
Same author

GFI1 as a novel prognostic and therapeutic factor for AML/MDS.

Leukemia·2016
Same author

Quadriceps tendon rupture.

Orthopedics·2014
Same author

Habitual patella dislocation.

Orthopedics·2014

Area of Science:

  • Oncology
  • Medical Chemotherapy
  • Sarcoma Research

Background:

  • The European Organization on Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group has extensively studied chemotherapy for advanced disease.
  • Initial CYVADIC regimen (cyclophosphamide/vincristine/doxorubicin/dimethyl imidazole carboxamide) showed reduced efficacy, prompting component analysis.

Purpose of the Study:

  • To evaluate the efficacy of doxorubicin and ifosfamide chemotherapy regimens in advanced soft tissue and bone sarcomas.
  • To investigate the impact of dose optimization, particularly for doxorubicin, using bone marrow growth factors.

Main Methods:

  • Retrospective analysis of individual components of the CYVADIC regimen.
  • Conducting randomized trials comparing different chemotherapy combinations and doses.

Related Experiment Videos

  • Utilizing bone marrow growth factors to escalate chemotherapy doses.

    • Main Results:

    • Doxorubicin demonstrated significant activity as a single agent.
    • Ifosfamide (5 g/m2 over 24 hours) showed comparable activity to cyclophosphamide.
    • Previous trials indicated no significant benefit of doxorubicin/ifosfamide over single-agent doxorubicin due to dose differences.

    Conclusions:

    • Doxorubicin and ifosfamide are key components for advanced sarcoma chemotherapy.
    • Optimizing chemotherapy doses, especially doxorubicin, with growth factors is under investigation.
    • Ongoing randomized trials aim to confirm improved response rates and outcomes with intensified regimens.